# EDGAR Filing Document

**Accession Number:** 0001888014
**File Stem:** 0000000000-25-010427
**Filing Date:** 2025-9
**Character Count:** 2217
**Document Hash:** 76364ccd231a65c3c0e66694476f7d2e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010427.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0000000000-25-010427

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250924

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AKANDA CORP.
- **CENTRAL INDEX KEY:** 0001888014
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290367

**BUSINESS ADDRESS:**
- **STREET 1:** 1A, 1B LEAROYD ROAD
- **CITY:** NEW ROMNEY
- **STATE:** X0
- **ZIP:** TN28 8XU
- **BUSINESS PHONE:** 442034889514

**MAIL ADDRESS:**
- **STREET 1:** 77 KING STREET WEST, SUITE 400
- **STREET 2:** C/O DENTONS CANADA LLP
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 0A1
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-089085

## Text-Extract

```

                                                           September 24, 2025

Katie Field
Interim Chief Executive Officer and Executive Director
Akanda Corp.
100 King St. W, Suite 1600
Toronto, ON M5X 1G5 , Canada

        Re: Akanda Corp.
            Registration Statement on Form F-1
            Filed September 18, 2025
            File No. 333-290367
Dear Katie Field:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Alan Campbell at 202-551-4224 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Samantha M. Guido

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._